This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
For patients with chronic hepatitis B virus infection (CHB), serum mac-2-binding protein glycosylation isomer (M2BPGi) is a reliable marker for assessing liver fibrosis, according to results published in Clinical and Translational Gastroenterology.
M2BPGi presents a noninvasive alternative to the standard invasive liver biopsy for assessing liver fibrosis in CHB. Furthermore, M2BPGi appears to correlate well with histologic stages of liver fibrosis.
After multivariate analysis, the researchers found that MSBPGi was the most significant independent factor for ≥F3 compared with aspartate aminotransferase to platelet ratio, aspartate aminotransferase to alanine aminotransferase ratio, and fibrosis index based on 4 factors (odds ratio, 8.197; 95% CI, 2.699-24.897; P <.001).
“Serum M2BPGi is a potential marker to conveniently diagnose F3/F4 without needing a liver biopsy,” the study authors concluded.